Brokerages Set Phreesia, Inc. (NYSE:PHR) Target Price at $31.33

Shares of Phreesia, Inc. (NYSE:PHR - Get Free Report) have received an average rating of "Buy" from the twelve brokerages that are covering the company, MarketBeat.com reports. Twelve research analysts have rated the stock with a buy rating. The average twelve-month target price among analysts that have covered the stock in the last year is $31.33.

PHR has been the topic of several recent analyst reports. KeyCorp reduced their target price on shares of Phreesia from $30.00 to $28.00 and set an "overweight" rating on the stock in a research note on Wednesday, April 16th. Piper Sandler restated an "overweight" rating and issued a $33.00 target price (up from $31.00) on shares of Phreesia in a research note on Wednesday, January 29th. Canaccord Genuity Group increased their price target on Phreesia from $34.00 to $35.00 and gave the stock a "buy" rating in a research report on Thursday, March 13th. DA Davidson cut their price objective on shares of Phreesia from $36.00 to $34.00 and set a "buy" rating on the stock in a report on Monday, April 14th. Finally, Royal Bank of Canada upgraded shares of Phreesia from a "sector perform" rating to an "outperform" rating and raised their price target for the company from $24.00 to $32.00 in a report on Wednesday, January 8th.

Phreesia Trading Down 0.2 %

Shares of Phreesia stock traded down $0.04 on Friday, reaching $24.82. The company had a trading volume of 115,082 shares, compared to its average volume of 429,793. The firm's 50-day moving average price is $25.34 and its two-hundred day moving average price is $24.45. Phreesia has a 1 year low of $17.07 and a 1 year high of $30.53. The firm has a market cap of $1.46 billion, a price-to-earnings ratio of -16.88 and a beta of 0.82. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.74 and a quick ratio of 1.74.

Insider Buying and Selling at Phreesia

In other Phreesia news, SVP David Linetsky sold 4,499 shares of the firm's stock in a transaction dated Wednesday, April 16th. The stock was sold at an average price of $23.73, for a total transaction of $106,761.27. Following the transaction, the senior vice president now owns 217,239 shares of the company's stock, valued at approximately $5,155,081.47. This trade represents a 2.03 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Yvonne Hui sold 1,878 shares of the stock in a transaction that occurred on Tuesday, April 8th. The shares were sold at an average price of $23.85, for a total value of $44,790.30. Following the completion of the sale, the insider now directly owns 28,449 shares of the company's stock, valued at $678,508.65. The trade was a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 112,660 shares of company stock valued at $3,124,263 in the last quarter. Corporate insiders own 5.80% of the company's stock.

Institutional Investors Weigh In On Phreesia

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Johnson Financial Group Inc. grew its stake in shares of Phreesia by 381.3% in the 4th quarter. Johnson Financial Group Inc. now owns 1,131 shares of the company's stock valued at $28,000 after purchasing an additional 896 shares during the last quarter. R Squared Ltd acquired a new position in shares of Phreesia during the fourth quarter worth about $30,000. BankPlus Trust Department acquired a new stake in shares of Phreesia in the 4th quarter valued at approximately $34,000. Quarry LP lifted its holdings in Phreesia by 210.9% in the fourth quarter. Quarry LP now owns 2,835 shares of the company's stock valued at $71,000 after acquiring an additional 1,923 shares during the period. Finally, KBC Group NV purchased a new stake in shares of Phreesia during the 1st quarter worth $74,000. 92.10% of the stock is owned by hedge funds and other institutional investors.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.